Published in Pigment Cell Melanoma Res on June 28, 2007
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol (2011) 1.50
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Br J Cancer (2016) 1.41
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One (2011) 1.11
DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res (2011) 1.08
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res (2011) 1.05
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One (2009) 1.03
Single-cell gene expression signatures reveal melanoma cell heterogeneity. Oncogene (2014) 1.01
Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res (2009) 0.96
CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer (2011) 0.93
Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res (2012) 0.90
Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer (2010) 0.90
MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor. PLoS One (2015) 0.88
Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics (2011) 0.86
Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85
Cellular Mechanisms of Oxidative Stress and Action in Melanoma. Oxid Med Cell Longev (2015) 0.84
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. Br J Cancer (2014) 0.84
DNA methylation characteristics of primary melanomas with distinct biological behaviour. PLoS One (2014) 0.84
Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clin Exp Metastasis (2009) 0.83
MiR-21: an environmental driver of malignant melanoma? J Transl Med (2015) 0.82
Expression of two WFDC1/ps20 isoforms in prostate stromal cells induces paracrine apoptosis through regulation of PTGS2/COX-2. Br J Cancer (2016) 0.81
Constitutional promoter methylation and risk of familial melanoma. Epigenetics (2014) 0.78
The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy. Cancer Invest (2011) 0.78
Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker. Int J Mol Sci (2012) 0.78
Association of TNFRSF10D DNA-methylation with the survival of melanoma patients. Int J Mol Sci (2014) 0.77
New Perspectives of "omics" Applications in Melanoma Research. Open Biochem J (2011) 0.77
Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel) (2010) 0.77
Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma. Melanoma Res (2011) 0.76
The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. PLoS One (2017) 0.75
Pre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation. Oncotarget (2016) 0.75
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics (2017) 0.75
Casticin inhibits the activity of transcription factor Sp1 and the methylation of RECK in MGC803 gastric cancer cells. Exp Ther Med (2016) 0.75
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology (2017) 0.75
Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance. Ann Transl Med (2015) 0.75
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment. PLoS One (2017) 0.75
Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia. Blood Cancer J (2017) 0.75
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Structure and function of flavivirus NS5 methyltransferase. J Virol (2007) 2.93
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res (2006) 2.72
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells (2008) 1.70
Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer (2004) 1.67
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer (2010) 1.50
Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PLoS One (2011) 1.49
Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J Virol (2007) 1.48
West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J Virol (2008) 1.44
Osteoporosis treatment following hip fracture: how rates vary by service. South Med J (2010) 1.40
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol (2009) 1.37
The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem (2009) 1.36
Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res (2004) 1.35
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res (2008) 1.33
Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res (2005) 1.32
Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods (2008) 1.28
Carcinosarcoma of the breast: two case reports and review of the literature. Cases J (2009) 1.26
Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Rev (2009) 1.23
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS One (2013) 1.22
Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res (2005) 1.15
Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg (2007) 1.15
B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer (2011) 1.12
Activated stat-3 in melanoma. Cancer Control (2008) 1.11
NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets (2008) 1.11
Successful removal of a giant intrathoracic lipoma: a case report and review of the literature. Cases J (2008) 1.10
Epigenetics in human melanoma. Cancer Control (2009) 1.09
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer (2013) 1.08
The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets (2008) 1.07
Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun (2012) 1.06
Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS. J Proteome Res (2006) 1.06
Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res (2009) 1.04
Separate molecules of West Nile virus methyltransferase can independently catalyze the N7 and 2'-O methylations of viral RNA cap. Virology (2008) 1.03
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther (2011) 1.03
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
A personalized microRNA microarray normalization method using a logistic regression model. Bioinformatics (2009) 1.01
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer (2012) 1.01
Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother (2006) 1.01
CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics (2008) 1.00
Overexpression of the progestagen-associated endometrial protein gene is associated with microphthalmia-associated transcription factor in human melanoma. Ochsner J (2011) 0.99
miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem (2012) 0.98
S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis (2003) 0.98
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med (2007) 0.97
Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer (2010) 0.97
Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther (2006) 0.97
Rac1 activity regulates proliferation of aggressive metastatic melanoma. Exp Cell Res (2007) 0.95
Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). J Biol Chem (2013) 0.95
Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control (2005) 0.94
Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med (2006) 0.94
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun (2013) 0.92
Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer? Int J Mol Med (2006) 0.92
B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Front Biosci (Elite Ed) (2011) 0.91
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer (2010) 0.90
Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res (2010) 0.90
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis (2007) 0.90
The impact of genomics in understanding human melanoma progression and metastasis. Cancer Control (2008) 0.89
Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002) 0.88
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg (2004) 0.88
Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease. Eur J Haematol (2007) 0.88
Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol (2012) 0.87
Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology (2010) 0.87
Upregulation of Fanconi anemia DNA repair genes in melanoma compared with non-melanoma skin cancer. J Invest Dermatol (2011) 0.87
Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance. FEBS Lett (2012) 0.87
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer (2008) 0.87
Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol (2011) 0.85
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer (2002) 0.85
Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res (2004) 0.85
Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med (2010) 0.85
Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy. Cancer Gene Ther (2002) 0.85
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol (2004) 0.85
Current concepts in biobanking: development and implementation of a tissue repository. Front Biosci (Schol Ed) (2009) 0.85
Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem Biophys Res Commun (2002) 0.84
MicroRNA in Melanoma. Ochsner J (2010) 0.84
Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells. J Immunother (2010) 0.84
Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clin Exp Metastasis (2009) 0.83
Functional characterization of the progestagen-associated endometrial protein gene in human melanoma. J Cell Mol Med (2009) 0.83
Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status. Int J Cancer (2005) 0.83
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther (2005) 0.83